

# APRISE Study:

## Pancreatic cancer screening for high-risk individuals

Pancreatic cancer is the third leading cause of cancer death in Australia<sup>1</sup>. Most pancreatic cancer cases are diagnosed at Stage 4<sup>1</sup>. However, if found early, pancreatic cancer has a better chance of survival.

Individuals with a familial or genetic predisposition have a 10- to 20-fold increased lifetime risk of developing pancreatic cancer. Evidence shows that screening can lead to earlier detection, and increase the chance of curative treatment<sup>2</sup>.

The **A**ustralian **P**ancreatic high-**R**isk **S**crEening (APRISE) Study is a national study that will screen high-risk individuals with a familial and/or genetic predisposition to pancreatic cancer.

### Who is eligible?

Patients may be eligible if they:

- > Are aged 18-90 years and
- > Have no personal history of pancreatic cancer and
- > Have a familial or genetic risk, including:
  - Strong family history of pancreatic cancer or
  - A confirmed pathogenic genetic variant (e.g., *BRCA1*, *BRCA2*, *PALB2*, *ATM*, *MLH1*, *MSH2*, *MSH6*, *PMS2*, *EPCAM*, *CDKN2A*, *STK11*, *PRSS1*) or
  - Diagnosis of Peutz-Jeghers Syndrome, Hereditary Pancreatitis, or Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)

### What does participation involve?

Participation will involve:

- > Baseline MRI and/or endoscopic ultrasound
- > Specialist review with follow-up appointments and assessments as clinically indicated
- > Annual questionnaires

### Informing and referring eligible patients

If you have a patient who meets the eligibility criteria, you can:

- > **Tell them about the APRISE Study** – Explain that early detection through surveillance may improve outcomes for high-risk individuals.
- > **Provide them with our details** – Patients can contact the study team directly if they are interested.
- > **Refer them to the study** – If the patient agrees, you can contact the study team on their behalf.



**For more information on participating sites across Australia or to refer a patient, contact us at 0418 370 684 or visit our website by scanning the QR code.**

This study is proudly funded by Epworth HealthCare, PanKind – The Australian Pancreatic Cancer Foundation, the Viridian Foundation, and the Victorian Government through the Victorian Cancer Agency.

### References

1. Australian Institute of Health and Welfare (AIHW) 2024, *Cancer data in Australia*, <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia>
2. Goggins M et al.; International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. *Gut*. 2020 Jan;69(1)